| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6004968 | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(6 years ago) | |
|
US6004968 (Pediatric) | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(5 years ago) | |
Epivir is owned by Viiv Hlthcare.
Epivir contains Lamivudine.
Epivir has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Epivir are:
- US5905082
- US5905082*PED
- US6004968
- US6004968*PED
- US5905082
Epivir was authorised for market use on 17 November, 1995.
Epivir is available in tablet;oral, solution;oral dosage forms.
Epivir can be used as treatment of hiv.
The generics of Epivir are possible to be released after 20 September, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using LAMIVUDINE ingredient
Market Authorisation Date: 17 November, 1995
Treatment: Treatment of hiv
Dosage: TABLET;ORAL; SOLUTION;ORAL
More Information on Dosage
EPIVIR family patents
